AN2 Therapeutics (ANTX) Other Accumulated Expenses (2021 - 2026)
AN2 Therapeutics (ANTX) reported Other Accumulated Expenses of $567000.0 for Q1 2026, up 829.51% year-over-year from $61000.0 in Q1 2025, and up 1034.0% quarter-over-quarter from $50000.0 in Q4 2025.
AN2 Therapeutics (ANTX) Other Accumulated Expenses (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Other Accumulated Expenses data on file, last reported at $567000.0 in Q1 2026.
- Other Accumulated Expenses for Q1 2026 came in at $567000.0, up 829.51% year-over-year; the trailing twelve-month figure through Mar 2026 was $567000.0 (up 829.51% YoY), and the FY2025 annual result was $50000.0, down 93.68% from the prior year.
- Other Accumulated Expenses rose to $567000.0 in Q1 2026 per ANTX's latest filing, from $50000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $1.3 million in Q3 2024 and troughed at $9000.0 in Q2 2022.
- A 5-year average of $361400.0 and a median of $102000.0 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2025 and 2026: Other Accumulated Expenses tumbled 97.41% in 2025, then surged 829.51% in 2026.
- A 5-year view of Other Accumulated Expenses shows it stood at $122000.0 in 2022, then dropped by 16.39% to $102000.0 in 2023, then jumped by 675.49% to $791000.0 in 2024, then tumbled by 93.68% to $50000.0 in 2025, then jumped by 1034.0% to $567000.0 in 2026.
- Business Quant data shows ANTX's Other Accumulated Expenses at $567000.0 in Q1 2026, $50000.0 in Q4 2025, and $33000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 50,000.00 |
| Sep 30, 2025 | 33,000.00 |
| Jun 30, 2025 | 717,000.00 |
| Mar 31, 2025 | 61,000.00 |
| Dec 31, 2024 | 791,000.00 |
| Sep 30, 2024 | 1.28 Mn |
| Jun 30, 2024 | 559,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | 102,000.00 |
| Sep 30, 2023 | 973,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 122,000.00 |
| Jun 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 33,000.00 |
| Dec 31, 2021 | 41,000.00 |